MH002, a 6-strain Optimized Consortium in Clinical Development for Ulcerative Colitis & Pouchitis

Time: 12:00 pm
day: Conference Day Two Track B AM 1


  • Discover how MH002 was developed through MRM Health’s proprietary CORAL® platform, allowing manufacturing of complete consortia in a single process
  • Reviewing MH002’s multifactorial mechanism-ofaction includes gut barrier restoration, mucosal healing and immunomodulation
  • Sharing a status update of both ongoing clinical trials